The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective.

Autor:	Alroughani R; Division of Neurology, Department of Medicine, Al Amiri Hospital, Kuwait., Van Wijmeersch B; Universiteit Hasselt and Rehabilitation & MS-Centre Pelt, Belgium., Al Khaboori J; Khoula Hospital, Mina Al Fahal, Muscat, Oman., Alsharoqi IA; Salmaniya Medical Complex, Bahrain., Ahmed SF; Ibn Sina Hospital, Kuwait., Hassan A; Tawam Hospital, Al Ain, Abu Dhabi, United Arab Emirates., Inshasi J; Rashid Hospital, Dubai, United Arab Emirates., Krieger DW; Mediclinic Hospital, Dubai, United Arab Emirates., Shakra M; Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates., Shatila AO; Al Mafraq Hospital, Abu Dhabi, United Arab Emirates., Szolics M; Tawam Hospital, Al Ain, Abu Dhabi, United Arab Emirates., Khallaf M; Sanofi Genzyme, Dubai, United Arab Emirates., Ezzat A; Sanofi Genzyme, Dubai, United Arab Emirates.
Jazyk:	angličtina
Zdroj:	Therapeutic advances in neurological disorders [Ther Adv Neurol Disord] 2020 Sep 16; Vol. 13, pp. 1756286420954119. Date of Electronic Publication: 2020 Sep 16 (Print Publication: 2020).
DOI:	10.1177/1756286420954119
Abstrakt:	Over the past decade, the development of high-efficacy disease-modifying therapies (DMTs) has been responsible for more effective management of relapsing-remitting multiple sclerosis (RRMS). However, the gaps in optimal care for this complex disease remain. Alemtuzumab (Lemtrada®) is a highly efficacious DMT that shows better patient outcomes and therapeutic benefits, but its use is under-recognized in the Gulf region. Experts in the care of multiple sclerosis shared their opinions based on study data and daily clinical experience in identifying the appropriate patient profile suitable for alemtuzumab's therapeutic benefits. Age, disease activity and severity, disability status, physician experience, and economic condition are some of the key indicators for alemtuzumab use. Competing Interests: Conflict of interest statement: Jabber Al Khaboori declared no conflict of interest and has received honoraria from Sanofi Genzyme. Raed Alroughani received honoraria as a speaker and for serving in scientific advisory boards from Bayer, Biogen, Merck, Novartis, Roche, and Sanofi. Isa Ahmed Alsharoqi has received sponsorship from Sanofi Genzyme for this publication. Ali Hassan has received honoraria for advisory boards from Sanofi and lectures from Roche and Allergan. Jihad Inshasi has been a recipient of advisor and speaker honorarium from Sanofi and primary investigator (PI) of Lemlife Alemtuzumab Study at Rashid Hospital. He has been a recipient of adviser and speaker honorarium from Roche and principal investigator (PI) of Consonance study at Rashid Hospital, DHA. Derk W. Krieger has been an advisor Sanofi and primary investigator (PI) of Lemlife Alemtuzumab Study at Mediclinic City Hospital, Dubai. He has received honoraria for lectures from Roche on Ocrelizumab program. Mustafa Shakra has received honoraria for advisory boards and lectures from Sanofi Merck Novartis Biogen and Roche. Ahmed Osman Shatila has been a beneficiary of lecture honoraria for Sanofi-Genzyme, Merck, Genpharm, Roche, Novartis, Boehringer Ingelheim, Biologix, as well as advisory board honoraria from Sanofi-Genzyme, Roche, Novartis, Pfizer, Biologix. His educational conferences travel and registration and hotel received sponsorship from Sanofi Genzyme, Merck, Genpharm, Roche, Novartis, Biologix. Bart Van Wijmeersch has received Research and Travel Grants, Honoraria for MS-Expert Advice, and Speakers Fees from Actelion, Bayer-Schering, Biogen-Idec, Sanofi/Genzyme, Merck-Serono, Novartis, Roche and TEVA. Samar F. Ahmed and Miklos Szolics have both received an honorarium from Sanofi Genzyme. Aly Ezzat and Mohamed Khalaf were employed by the company Sanofi Genzyme and contributed to the review and revision of the content. (© The Author(s), 2020.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu